ArticleJournal of molecular modeling2026
HopWD-DTA: a novel framework for drug-target affinity prediction fusing multi-hop neighborhoods and deep features.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAccurate prediction of drug-target affinity (DTA) is crucial for accelerating drug discovery, but it remains a significant challenge. While deep learning methods have shown promise, many existing models struggle with representing long-range protein relationships within protein-protein interaction (PPI) networks, often suffering from performance degradation as graph neural network layers deepen. To overcome this limitation, we developed HopWD-DTA, a novel framework designed to effectively capture both local and global protein features. The core innovation lies in integrating multi-hop neighborhood information from PPI networks with deep structural features of proteins and drugs. Comprehensive evaluations on the Davis, KIBA, and Human benchmark datasets demonstrate that HopWD-DTA achieves state-of-the-art performance, significantly improving DTA prediction accuracy over existing cutting-edge solutions.
methodsThe HopWD-DTA framework consists of separate branches for protein and drug feature extraction. For proteins, structural features from residue contact maps are first encoded using a Graph Convolutional Network (GCN). These features, along with InterPro annotations, are then embedded into a PPI network. We introduce a multi-hop neighborhood serialization technique, which generates a sequence of feature matrices representing different neighborhood scopes. This sequence is processed by a Variational Autoencoder (VAE) to learn a robust protein representation. For drugs, molecules are represented as graphs from SMILES strings and encoded via a GCN, followed by a novel Wide-and-Deep Path (WDPATH) module to capture both macroscopic and microscopic features. The final protein and drug features are concatenated and fed into a multilayer perceptron for affinity prediction. The model was implemented using PyTorch and RDKit.
Indexed as
Identifiers
41973256What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.